How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/disitamab-vedotin-tislelizumab-oxaliplatin-capecitabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine (Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: antibody-drug conjugate, PD-1 inhibitor, platinum agent, and antimetabolite. Are

phase 3 Combination therapy: antibody-drug conjugate, PD-1 inhibitor, platinum agent, and antimetabolite HER2, PD-1, DNA (via oxaliplatin and capecitabine) Oncology Biologic Live · refreshed every 30 min

Target snapshot

Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine (Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine) — RemeGen Co., Ltd.. This combination therapy targets HER2-positive gastric cancer through antibody-drug conjugate-mediated tumor cell killing, immune checkpoint inhibition, and chemotherapy-induced DNA damage.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine TARGET	Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine	RemeGen Co., Ltd.	phase 3	Combination therapy: antibody-drug conjugate, PD-1 inhibitor, platinum agent, and antimetabolite	HER2, PD-1, DNA (via oxaliplatin and capecitabine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: antibody-drug conjugate, PD-1 inhibitor, platinum agent, and antimetabolite class)

RemeGen Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/disitamab-vedotin-tislelizumab-oxaliplatin-capecitabine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab